(NASDAQ: INCY) Incyte's forecast annual revenue growth rate of 9.82% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.86%.
Incyte's revenue in 2025 is $4,241,217,000.On average, 10 Wall Street analysts forecast INCY's revenue for 2025 to be $903,314,963,165, with the lowest INCY revenue forecast at $890,585,511,996, and the highest INCY revenue forecast at $930,943,079,945. On average, 10 Wall Street analysts forecast INCY's revenue for 2026 to be $999,533,528,266, with the lowest INCY revenue forecast at $942,505,966,333, and the highest INCY revenue forecast at $1,065,953,407,479.
In 2027, INCY is forecast to generate $1,085,321,517,951 in revenue, with the lowest revenue forecast at $1,005,382,221,172 and the highest revenue forecast at $1,226,226,403,662.